Online inquiry

IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8725MR)

This product GTTS-WQ8725MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CCR5 gene. The antibody can be applied in AIDS, Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000579.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1234
UniProt ID P51681
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8725MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14831MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ15299MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ6092MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ7094MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ4884MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ12974MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ263MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ10467MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2541546
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW